Where does Incyte Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Incyte Corporation ranks #693 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Incyte Corporation hold?

Incyte Corporation holds 652 US utility patents granted between 2015 and 2025, spanning 22 technology areas.

What is Incyte Corporation's Innovation Score?

Incyte Corporation has an Innovation Score of 61.5 out of 100 (top 3% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Incyte Corporation's patent grant rate increasing or decreasing?

Incyte Corporation's recent grant velocity is +3% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Incyte Corporation's patents?

Incyte Corporation's patents average 26.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Incyte Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Incyte Corporation

Q: What technology areas does Incyte Corporation focus on?

Incyte Corporation's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 605 patents. Grants appear in 22 CPC subclasses total.

USPTO PatentsView assignee record - 652 granted patents across 22 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Incyte ranks #693 of 49,997 tracked US assignees by granted-patent volume, with 652 patents across 22 technology areas.

#693
of 49,997 US assignees by volume: Top 3%
by Innovation Score (61.5/100): 26.1
avg claims per patent: +3%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R693 · US Corporation #693 · 652 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-STRONG · CLAIMS-DENSE · TYPE-USCORP · VEL-FLAT · BOOK-FULL

GRANTS-MID 652 grants
TOP-DECILE #693/49,997
PHOTO-FINISH Hughes Network Systems
CPC-FOCUS A61P · 22 areas
INNOV-STRONG 61.5/100
CLAIMS-DENSE 26.1 claims/avg
TYPE-USCORP US Corporation
VEL-FLAT +3% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Hughes Network Systems, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Incyte · this assignee

61
National Research… · near

61
Rite-Hite Holding · near

61
Fameccanica Data S p A · near

61
Avaya · near

61
3D Lighting… · lowest

7

What this shows Incyte's Innovation Score is 61.5/100 (top 3% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Incyte's grants concentrate

Incyte Corporation is a focused PatentsView assignee: 22 CPC subclasses with 92.8% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (72 grants) versus a trough of 43 in 2015. By volume, Incyte sits between Roche Diagnostics Operations, Inc. and Time Warner Cable Enterprises LLC.

Incyte's three-year grant acceleration

From 2019–2021 to 2022–2024, Incyte Corporation moved from 177 to 199 grants (1.12x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #915. See the growth leaderboard.

Roche Diagnostics…

654
psemi

654
Nederlandse Organ…

653
Hughes Network Sy…

652
University of Sou…

652
Incyte ◀

652
British Telecommu…

651
BYD

651
Time Warner Cable…

651

What this shows Incyte holds 652 patents at rank #693, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Incyte

By rank, the assignees closest to #693 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Incyte's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Incyte, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (61 here).

National Research Council of Canada 61 Rite-Hite Holding Corporation 61 Fameccanica.Data S.p.A. 61 Avaya Inc. 61

Similar claim depth

Nearest assignees by average claims per patent (26.1 here).

Alnylam Pharmaceuticals, Inc. 26.0 avg Novozymes, Inc. 26.0 avg Milestone Entertainment, LLC 26.1 avg Omya International AG 26.0 avg

Incyte's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

61 Top 3% higher than 97% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Incyte Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	43	6.6%
2016	57	8.7%
2017	72	11.0%
2018	64	9.8%
2019	65	10.0%
2020	58	8.9%
2021	54	8.3%
2022	65	10.0%
2023	64	9.8%
2024	70	10.7%
2025partial year	40	6.1%

Which technologies does Incyte Corporation patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 605

C07D - Heterocyclic Compounds 566

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 369

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 89

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 31

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 24

C07C - Acyclic OR Carbocyclic Compounds 22

Y02A - Technologies FOR Adaptation TO Climate Change 20

C07K - Peptides 18

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 15

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 7

A01M - Catching, Trapping OR Scaring OF Animals ; Apparatus FOR THE Destruction OF Noxious Animals OR Noxious Plants 5

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 4

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 3

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 2

Top 15 of 22 technology areas

Where it ranks

Overall rank by patents

#693

of 49,997 tracked assignees

Innovation Score

61.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Incyte Corporation's patent record in context - here's where to go next.

Incyte Corporation's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 92.8% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #693 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Incyte Corporation against Roche Diagnostics Operations, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 61.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.